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 ABSTRACT 
 
Purpose of review: Ulcerative colitis (UC) and Crohn’s Disease (CD) are the two predominant 
types of inflammatory bowel disease (IBD), affecting over 1.4 million individuals in the US. IBD 
results from complex interactions between pathogenic components, including genetic and 
epigenetic factors, the immune response and the microbiome through an unknown sequence of 
events. The purpose of this review is to describe a system biology approach to IBD as a novel 
and exciting methodology aiming at developing novel IBD therapeutics based on the integration 
of molecular and cellular “omics” data. 
 
Recent Findings: Recent evidence suggested the presence of genetic, epigenetic, 
transcriptomic, proteomic and metabolomic alterations in IBD patients. Furthermore, several 
studies have shown that different cell types, including fibroblasts, epithelial, immune and 
endothelial cells together with the intestinal microbiota are involved in IBD pathogenesis. Novel 
computational methodologies have been developed aiming to integrate high-throughput 
molecular data.  
 
Summary: A systems biology approach could potentially identify the central regulators (hubs) in 
the IBD interactome and improve our understanding of the molecular mechanisms involved in IBD 
pathogenesis. The future IBD therapeutics should be developed on the basis of targeting the 
central hubs in the IBD network. 
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Introduction 
IBD is a multifactorial disease with several components contributing to its pathogenesis1. 
Alterations in the gut microbiota2-5, activation of different immune cell types6-8, changes in the 
vascular endothelium9, 10 and alterations in the structure of tight junctions in colonocytes11-13 
perturb the gut cellular interactome resulting in IBD development. Each cell population in the gut 
has its own complex molecular interactions (interactome), consisting of genetic, epigenetic, 
transcriptional, protein and secreted factors. The isolated modulation of one component in the 
cellular and molecular gut interactomes might be insufficient to provide an effective therapeutic 
solution for IBD patients. A major problem that researchers in the IBD field face is how to integrate 
the continuously generated data derived from novel technologies and collectively characterize 
and quantitate the roles, relationships and actions of various types of molecules, referred to as 
“omics”, and develop novel therapeutics that would target these interactomes instead of a specific 
signaling pathway or cellular population. In the last five years, the explosion in the development 
of novel computational and high-throughput technologies14, 15 has enabled us to study different 
human diseases in a genome-wide level. Here, we will discuss how these technologies, through 
integration of high throughput cellular, molecular and clinical data, could contribute to our 
understanding of IBD pathogenesis and the development of novel drugs for IBD patients. 
 
Systems Approach in IBD 
A system is an entity that maintains its existence through the interactions of its parts. A systems 
approach consists of four major steps: a) identify the parts of the system; b) characterize the 
properties of the parts; c) identify the interaction between the parts; and d) evaluate the 
interactions between the parts and the environment16. A systems approach can be applied in IBD, 
aiming at identifying and understanding the complex interactions between different cell types 
(parts) in the gut (system) and determine whether these interactions are deregulated during IBD 
pathogenesis. The development of high throughput technologies to analyze the entire set of 
genes (genome), epigenetic modifications (epigenome) and transcriptional regulation 
(transcriptome), and the identification of novel algorithms and software able to integrate the 
“omics” data enabled the genesis of the systems biology field. During IBD development there are 
perturbations of the molecular and cellular gut interactomes. In this review, we will present the 
state of the art high throughput technologies that are available to study the IBD interactomes and 
describe novel computational tools able to integrate the “omics” information. The systems biology 
strategy is very promising aiming to expedite the drug discovery process in IBD.  
 
 
Molecular Systems Approach in IBD 
Previous studies have revealed the significance of genetic variations in IBD pathogenesis by 
performing large genome-wide association studies (GWAS)17.  However, the genetic variants that 
have been associated with UC and CD can only explain the 20-25% of all IBD cases, suggesting 
the presence of additional contributing factors18.  One of the striking aspects of IBD is its 
substantially increased incidence during the last decades, suggesting the potential involvement 
of environmental (epigenetic) factors in IBD pathogenesis19.  Moreover, the completion of the 
ENCODE project last year20 identified >100,000 novel transcripts that may be involved in IBD 
development.  To build and characterize the IBD molecular interactome, we should first 
characterize its components (Figure 1) and then identify their complex interactions, by performing 
computational analysis. 
 
A. Characterization of the IBD Genome  
Genomics is defined as the study of genetic alterations in the genome-wide level.  GWAS has 
been performed in large numbers of IBD patients, resulting in the identification of novel variants21.  
Recently an assay, called ImmunoChip, has been developed including 200,000 single nucleotide 
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polymorphisms (SNPs) relevant to IBD and other immune-mediated diseases22.  Studies of SNPs 
and insertion-deletion polymorphisms identified a total of 163 loci associated with IBD and 
revealed important pathways involved in IBD pathogenesis such as host-microbe interactions and 
autophagy5, 21.  These studies identified genomic regions that influence the risk of disease but 
cannot on their own determine specific causative roles.  In fact, from the 163 loci only a handful 
has shown functional IBD-associated SNPs23.  Exome sequencing analysis is informative for the 
whole spectrum of variation within the protein coding sequence of genes and carries the potential 
of identifying the missing heritability in complex diseases such as IBD.  Recently, whole exome 
sequencing (the sequencing of the complete coding regions of the genome) applied in CD and 
pediatric IBD patients revealed novel low-frequency variants in known IBD genes24, 25.  Although 
all these approaches have contributed significantly to our knowledge of genetic alterations in IBD 
patients, up to date there is no study of sequencing the whole genome of IBD patients.  This 
analysis will provide a comprehensive view of genetic alterations in IBD patients and potentially 
will identify novel SNPs and mutations in the genomes of IBD patients.  
 
B. Studying the IBD Epigenome  
  In addition to the genomic analysis, modifications could occur in the epigenetic level, affecting 
gene expression.  Epigenetics is defined as cellular information that is heritable during cell division 
but is not encoded in the sequence of the genome.  Pathologic epigenetic changes, such as DNA 
methylation and histone modifications are increasingly considered as alternatives to mutations 
and chromosomal alterations in altering gene function26.  a) IBD DNA Methylome:  The increasing 
interest of the role of DNA methylation in IBD pathogenesis coincides with advances in platform-
based DNA methylation array technologies.  Employment of the Illumina 27K chip to analyze 
peripheral blood samples revealed fifty genes that were differentially methylated between CD 
patients with CD and controls27,28.  Furthermore, another study in 20 monozygotic twins discordant 
for UC identified 61 differentially methylated loci, including genes involved in inflammation29.  
However, none of these array technologies are able to study the DNA methylome at a genome-
wide level.  On the other hand, the DNA methylation-sequencing methodology will reveal the 
global DNA methylation alterations in IBD patients.  A recently developed technology, called 
reduced representation bisulfite sequencing (RRBS)30, requires low RNA amounts (10ng), even 
from paraffin-embedded samples, and is highly applicable to a wide range of IBD clinical samples. 
b) IBD Chromatin State:  In addition to DNA methylation, histone modifications play a critical 
role in gene regulation by affecting chromatin packaging.  A recent study revealed that cytokines 
could induce chromatin modifications in COL1A2 gene in intestinal mucosal endothelial cells31.  
Global histone modifications have been extensively studied in cancer and neurodegenerative 
diseases but despite evidence on their role in inflammation, their genome-wide distribution and 
function in IBD is still unknown.  To follow a systems biology approach, it is essential to perform 
chromatin immunoprecipitation-sequencing (ChIP-seq) analysis for active and suppressive 
chromatin marks in tissues and blood from IBD patients.  
 
C. Evaluation of the IBD Transcriptome The genome-wide expression catalogues the complete 
set of RNA transcripts, called transcriptome, produced by the genome, including coding and non-
coding RNAs.  cDNA microarray has been the main tool used to profile the global gene expression 
in IBD tissues or blood.  Previous studies have identified a gene signature in UC patients that 
correlates with disease activity32.  In addition to the coding genes, recent evidence suggested the 
presence of non-coding RNAs in the human genome, including microRNAs and large intergenic 
non-coding RNAs (lincRNAs)20.  By employing microRNA expression arrays and use of novel 
microRNA high-throughput profiling platforms, such as Nanostring33, microRNAs such as miR-
23a, miR-21, miR-29a, miR-124, and miR-192 have been found to be deregulated in colonic 
tissues and blood from IBD patients, and investigation of their mechanistic implications is currently 
underway34-37.  To date there is no study regarding the potential role of lincRNAs in IBD 
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pathogenesis.  Future studies should perform integrated expression analysis of coding and non-
coding RNAs in IBD patients by using the RNA-sequencing technology38.  This technology will 
reveal all the transcript variants that are potentially involved in IBD pathogenesis.  
 
D. Revealing the IBD Proteome  
Proteome is the complete set of expressed proteins, including their different isoforms and 
modifications.  The proteome corresponds to the structure and function of proteins and their 
higher-order complexes as well as their localization and translocation39-40.  A wide selection of 
proteomic approaches has been applied to characterize IBD pathogenesis by investigating the 
dynamic nature of the proteome41, including surface-enhanced laser desorption ionization 
(SELDI) or matrix-assisted laser desorption (MALDI)-time of flight (TOF) mass spectrometry (MS) 
and liquid chromatography (LC/MS) combined with two-dimensional gel electrophoresis.  Such 
proteomic studies have been performed for IBD using epithelial cell lines42-44, epithelial cells from 
colonic biopsies 45-47 and serum samples48-51.  Currently, the greatest interest in proteomic 
applications lays in identifying biomarkers in biofluids (such as serum and urine) or tissue samples 
(such as colonic biopsies)41 that are specific for UC and CD diseases and correlate with disease 
activity and other clinicopathological parameters.  
 
E. Constructing the IBD Metabolome  
The metabolome encompasses all the small molecules chemically transformed during cellular 
metabolism and provide a readout of cellular biochemistry52, 53.  The analytical techniques used 
to study the metabolome, include gas chromatography (GC), liquid chromatography (LC) and 
high/ultra-performance liquid chromatography (H/UPLC) followed by mass spectrometry (MS), 
and nuclear magnetic resonance spectroscopy (NMR)54.  Different metabolomic approaches have 
been applied in human biomaterials, including fecal water extracts, blood serum and urine 
samples, aiming to discriminate IBD patients from control subjects55-62.  Furthermore, 1H NMR 
spectroscopy and LC-MS have revealed distinct metabolic profiles between different intestinal 
compartments63. These data are very promising, suggesting the deregulation of the metabolome 
during IBD pathogenesis.  Additional studies should determine the significance of these findings 
in large cohorts of IBD patients, aiming to develop prognostic and diagnostic tests in the near 
future.  It is essential to integrate the proteomic and metabolomics data from IBD patients in order 
to fully characterize the biochemical map and its alterations during IBD development. 
 
Integration of IBD “Omics” Data  
Although there is a continuous generation of molecular “omics” data from biomaterials derived 
from IBD patients, there is a major challenge on how to analyze and integrate these data in order 
to identify the central regulators of IBD pathogenesis.  The network analysis could contribute to 
the construction of the IBD molecular interactome64.  The network theory is a branch of applied 
mathematics that uses the concepts of graph theory65, 66.  The development of the network theory 
was led by applications to the real-world examples, such as the social networks and technological 
(internet) networks.  The structure of complex molecular interactions in IBD can be represented 
by networks and not by linear signaling pathways, a methodology followed by most researchers 
today.  A network could reveal the positive and negative feedback loops and information 
exchange between the different signaling pathways.  Overlooking the loop circuits led to several 
failures of drugs developed by pharmaceutical companies67.  In an IBD network, nodes could 
correspond to genes, proteins or metabolites, while the edges will represent the interactions, 
causal influences or correlations between them (Figure 2).  To detect the central molecular 
regulators in IBD pathogenesis, the IBD network could be compared to random graphs with 
defined statistical properties68.  We can build networks based on the specific characteristics 
described above.  For example, we can build an IBD metabolic network of the metabolites 
deregulated in IBD patients and the chemical reactions that connect these metabolites.  An IBD 
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transcriptional network can be constructed by identifying transcriptional interactions between 
deregulated coding and non-coding RNAs.  A protein network will include the deregulated protein-
protein interactions in specific cell types.  The next step would be to integrate all these networks 
aiming to construct the IBD molecular interactome.   
 
IBD Network Construction and Visualization. 
An important question is how practically could we construct and visualize these IBD molecular 
networks?  The first step would be the generation of the “omics” data from IBD patient 
biomaterials.  Next, the dynamics and regulatory patterns of the potential gene, protein and 
metabolite interactions should be described by a mathematical graph.  The graph could be 
constructed using Boolean network analysis, Bayesian network analysis, ordinary and partial 
differential equation systems or stochastic processes69-73.  A graph consists of a discrete set of 
nodes (N) and edges (E), which are defined as pairs of nodes (Figure 2).  The nodes could be 
genes, proteins or metabolites deregulated in IBD and the edges will show direct or indirect 
interactions between the nodes. Each network will be characterized by its statistical properties74.  
The node that shares an edge with another node is called neighbor and the number of neighbors 
is called the degree or node size (k).  A distinction between in-degrees (kin) and out-degrees (kout) 
refers to incoming and outgoing edges, respectively.  The gene, protein or metabolite with the 
high number of incoming and outgoing edges is called central regulator or hub75.  The hubs 
identified by the network analysis could be used as IBD drug targets since they will central 
regulators of the IBD networks.  
In the last few years multiple software programs have been developed for systems biology 
purposes.  A visit to the software guide at www.sbml.org website will reveal more than 100 
different softwares developed for network and modeling analyses. JSIM is a Java-based software 
able to building IBD quantitative networks and can be used from a web browser76.  In addition, 
the CellDesigner is another Java-based tool that could show visually appealing graphical 
representations of the IBD networks77.  Furthermore, E-Cell is a Python-based software able to 
model, simulate and analyze large-scale IBD networks and systems78.  These tools require high 
knowledge of mathematics and computer programming, revealing the importance of integrating 
computational biologists in IBD research.  In addition to computational tools, there are 
commercially available tools that do not require computing knowledge.  A user-friendly software, 
called Ingenuity Pathway Analysis (IPA), constructs molecular networks based on experimental 
and literature-based data79.  These computational tools can integrate molecular “omics” data into 
networks for each of the cellular populations involved in IBD pathogenesis. 
 
Cellular Systems Approach in IBD 
Gut physiology is maintained through balance between the epithelial, immune, endothelial cells, 
fibroblasts and microbes.  Mucosal immunity is an important component of IBD pathogenesis, 
however, it is only a part of the IBD cellular interactome.  Gut microbiota can affect the function 
of regulatory T cells in the gut, contributing to IBD pathogenesis, while the proportion of the 
different luminal bacterial species changes significantly in IBD80, 81.  Investigating the changes in 
the number and the identity of the microbiome in IBD patients has revealed distinct patterns that 
could be linked to disease pathogenesis82, 83.  Lately, studies have focused on the functional 
consequences of IBD-associated dysbiosis.  Using a novel technique to isolate the microbes and 
the proteins84 or the metabolites85 from specific areas of the colon, investigators have shown an 
interdependence and a bi-directional influence of certain bacteria populations with specific 
pathways, thus identifying potentially important host–microbe interactions in IBD pathogenesis. 
Recent evidence showed the importance of vascular and lymphatic endothelium in IBD 
pathogenesis.  Blocking the intestinal angiogenesis has a beneficial effect in experimental 
colitis86, while inhibition of a major lymphangiogenic receptor exacerbates colonic inflammation87.  
Novel studies contribute to our understanding on the role of colonic epithelial cells and tight 
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junction structure and function in IBD pathogenesis88-90.  Thus, it is essential to continue 
characterizing these cellular populations and identify their molecular links, aiming at constructing 
the IBD cellular interactome.  The construction of the IBD cellular interactome should follow the 
same principles described for the IBD molecular interactome.  This will be realized by integrating 
the molecular networks in each of the gut components (cells, microbes) and construct a larger 
network which will reveal interactions between these different components.  The nodes in this 
network that link two different gut components would reveal how a perturbation in one component 
would affect the dynamics and properties of another component.  
 
IBD Drug Discovery and Systems Approach 
Although different cells and microbes are involved in IBD pathogenesis, modulation of one of 
these components alone may not lead to an IBD cure.  The mucosal immune system has been 
the focus of multiple therapeutic interventions in IBD, however the degree of success varies18.  
Alterations of the gut microbiota by probiotics have been used in IBD studies, but the benefits are 
variable and, more importantly, not permanent.  Thus, it is becoming more evident that 
manipulation of a specific cellular or microbial population in the gut may not lead to an IBD cure.  
Since the different cellular and microbial components are parts of the IBD cellular interactome, 
identification of drugs perturbing the IBD cellular interactome using systems biology approaches 
may have a greater therapeutic potential.  We propose to develop an IBD drug-molecular 
interactome map in the near future, based on the connectivity map platform91. This software tool 
will merge drug response hub signatures with the IBD interactome data, linking for the first time 
chemical compounds to IBD molecular networks.  This methodology could potentially identify 
novel and highly specific IBD drug targets that could expedite the IBD drug development process. 
 
Conclusion 
Taken together, it is essential in the near future to establish an IBD Interactome Consortium 
through collaboration between top IBD research centers in various countries.  This consortium 
should generate extensive “omics” knowledge from biomaterials (tissue, blood, urine, stool) 
derived from a well-characterized IBD cohort of patients, aiming to construct the IBD 
interactome in the near future, expediting the development of novel drugs for IBD patients 
through targeting the essential networks in this interactome.  We should take advantage of the 
exciting discoveries in biomedical technology field and transform them in novel therapeutics for 
IBD patients. 
 
 
 
 
Key Points 
• Integration of molecular and cellular “omics” is needed for a systems approach in IBD. 
• Development of novel therapeutics by targeting the central hubs of the IBD network. 
• To build IBD-interactome we should characterize its components and identify their interactions. 
• The drug-molecular interactome map will link chemical compounds to IBD molecular networks. 
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Figure 1.  Components of the molecular interactome 
The molecular interactome consists of alterations at the genomic, transcriptomic, proteomic and 
secretomic level.  In this interactome there are coding genes translated into proteins and non-
coding genes, such as microRNAs and lincRNAs, functioning as RNA molecules in the cell.  There 
are multiple complex interactions between transcripts, protein complexes and metabolites.  
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Figure 2.  Structure and graphical representation of a network 
A graph representing a network of nodes (A-H) and edges (arrows and lines).  There are 8 nodes 
and 11 edges.  The nodes could be genes, RNAs, proteins and metabolites while the edges would 
represent their interactions.  Network analysis could reveal the central regulator of the network.  
Manipulation in the expression levels of the central regulator would affect the whole network.  In 
this graph, node E has the highest number of edges, a total of seven, and can be called the central 
regulator or the hub of this specific network.  
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